Beam Therapeutics Inc. (BEAM)
BEAM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/0001193125-26-065194-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BEAM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001745999 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $139.7M |
| Net income | -$80.0M |
| Operating income | -$383.7M |
| Net margin | -57.2% |
| Operating margin | -274.6% |
| Revenue growth | +120.0% |
| Cash | $294.9M |
| Total assets | $1.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 15.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $213.3M cash; operating cash flow -$97.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 103,495,644 (2026-10-27); 101,474,944 a year earlier; 81,504,057 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-02-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $19.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $307K | -$134.4M | -$110.7M | $213.3M | $100.4M | $146.6M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $490K | -$122.7M | -$66.1M | $219.8M | $100.3M | $156.0M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $31.7M | -$94.3M | -$128.5M | $288.3M | $100.2M | $164.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $114.1M | $243.0M | -$83.3M | $294.9M | No debt tags | $139.7M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $9.7M | -$112.6M | -$81.5M | $268.0M | No debt tags | $55.7M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $8.5M | -$102.1M | -$76.5M | $282.1M | No debt tags | $60.3M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $7.5M | -$108.3M | -$103.9M | $527.9M | No debt tags | $63.6M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $30.1M | -$90.4M | -$76.4M | $282.0M | No debt tags | $63.5M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-03-10 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.6% |
| 1 month | -6.5% |
| 3 months | -13.9% |
| Year to date | -17.6% |
| 1 year | +5.4% |
| From 52-week high | -39.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| REPL | Replimune Group Inc. | $21.41 | -2.19% | $2.0B |
| BCRX | BioCryst Pharmaceuticals Inc. | $7.45 | -2.10% | $1.9B |
| MAZE | Maze Therapeutics Inc. | $33.90 | -1.25% | $1.9B |
| COAG | Hemab Therapeutics Holdings Inc. | $39.05 | -4.42% | $1.8B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier